Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 10/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25404502 | 1.00 | AXL (0.42) | AXLMERTKGSK3BDYRK1ASYK | |
| SCHEMBL25404507 | 1.00 | AXL (0.42) | AXLMERTKGSK3BDYRK1ASYK | |
| SCHEMBL25403543 | 0.88 | MET (0.41) | AXLMERTKGSK3BDYRK1AMET | |
| SCHEMBL25404620 | 0.88 | MET (0.41) | AXLMERTKGSK3BDYRK1AMET | |
| SCHEMBL25403541 | 0.88 | MET (0.41) | AXLMERTKGSK3BDYRK1AMET | |
| SCHEMBL26294076 | 0.83 | AXL (0.45) | AXLMERTKGSK3BDYRK1AMET | |
| SCHEMBL26294392 | 0.83 | AXL (0.45) | AXLMERTKGSK3BDYRK1AMET | |
| SCHEMBL26294378 | 0.81 | MAPK1 (0.43) | AXLMERTKGSK3BDYRK1AMET | |
| SCHEMBL25130635 | 0.80 | PIM1 (0.45) | AXLMET | |
| SCHEMBL26295453 | 0.80 | ACVR1B (0.46) | DYRK1AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | AXL 1370/4885MERTK 648/4885GSK3B 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.